- Home
- ARQT vs ADPT Comparison
ARQT vs ADPT Comparison
Compare ARQT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ADPT
- Stock Information
- Founded
- ARQT 2016
- ADPT 2009
- Country
- ARQT United States
- ADPT United States
- Employees
- ARQT N/A
- ADPT N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARQT Health Care
- ADPT Health Care
- Exchange
- ARQT Nasdaq
- ADPT Nasdaq
- Market Cap
- ARQT 1.7B
- ADPT 1.8B
- IPO Year
- ARQT 2020
- ADPT 2019
- Fundamental
- Price
- ARQT $15.00
- ADPT $11.82
- Analyst Decision
- ARQT Strong Buy
- ADPT Strong Buy
- Analyst Count
- ARQT 6
- ADPT 7
- Target Price
- ARQT $18.80
- ADPT $10.57
- AVG Volume (30 Days)
- ARQT 2.0M
- ADPT 2.4M
- Earning Date
- ARQT 08-13-2025
- ADPT 07-31-2025
- Dividend Yield
- ARQT N/A
- ADPT N/A
- EPS Growth
- ARQT N/A
- ADPT N/A
- EPS
- ARQT N/A
- ADPT N/A
- Revenue
- ARQT $212,819,000.00
- ADPT $189,527,000.00
- Revenue This Year
- ARQT $61.15
- ADPT $24.46
- Revenue Next Year
- ARQT $37.98
- ADPT $20.25
- P/E Ratio
- ARQT N/A
- ADPT N/A
- Revenue Growth
- ARQT 100.03
- ADPT 8.61
- 52 Week Low
- ARQT $7.86
- ADPT $3.51
- 52 Week High
- ARQT $17.75
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- ARQT 60.23
- ADPT 63.35
- Support Level
- ARQT $13.06
- ADPT $11.41
- Resistance Level
- ARQT $15.36
- ADPT $12.36
- Average True Range (ATR)
- ARQT 0.66
- ADPT 0.59
- MACD
- ARQT 0.12
- ADPT -0.01
- Stochastic Oscillator
- ARQT 82.57
- ADPT 72.65
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).